The incidence of genetic polymorphisms of CYP 2C in a Korean population

J. W. Ko, A. S. Macpherson, I. J. Jang, S. G. Shin, D. A. Flockhart

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The distribution of the genetic polymorphism for CYP2C19 in Asians seems different from that in Caucasians. No distribution of the mutations in CYP2C19 or CYP2C9 has been published in a Korean population. We determined the genotypes of 143 healthy, Korean volunteers for CYP2C19 (m1 and m2 mutations) and CYP2C9 (v1 mutation), and compared that to the distribution in a Caucasian population. The m1 and m2 mutations of CYP2C19 appear in significantly greater incidence in this Korean population than Caucasians (p<0.005), but the incidence of the v1 mutation of 2C9 is less in Koreans: P450 Genotypes Korean USA CYP2C19 m1/m1 0.13 0.09 m1/wt 0.39 0.28 m2/m2 0.01 0.00 m2/wt 0.28 0.12 m1/wt and m2/wt 0.09 0.00 CYP2C9 wt/wt 1.00 0.81 v1/v1 0.00 0.01 v1/wt 0.00 0.18 These data suggest that the incidence of Korean genetic poor metabolizers of CYP2C19 (0.22) is relatively large and that the v1 mutation of CYP2C9 is not prominent in Koreans.

Original languageEnglish
Pages (from-to)226
Number of pages1
JournalClinical Pharmacology and Therapeutics
Volume61
Issue number2
StatePublished - 1997

Fingerprint

Genetic Polymorphisms
Mutation
Incidence
Population
Genotype
Cytochrome P-450 CYP2C19
Healthy Volunteers
Cytochrome P-450 CYP2C9

ASJC Scopus subject areas

  • Pharmacology

Cite this

Ko, J. W., Macpherson, A. S., Jang, I. J., Shin, S. G., & Flockhart, D. A. (1997). The incidence of genetic polymorphisms of CYP 2C in a Korean population. Clinical Pharmacology and Therapeutics, 61(2), 226.

The incidence of genetic polymorphisms of CYP 2C in a Korean population. / Ko, J. W.; Macpherson, A. S.; Jang, I. J.; Shin, S. G.; Flockhart, D. A.

In: Clinical Pharmacology and Therapeutics, Vol. 61, No. 2, 1997, p. 226.

Research output: Contribution to journalArticle

Ko, JW, Macpherson, AS, Jang, IJ, Shin, SG & Flockhart, DA 1997, 'The incidence of genetic polymorphisms of CYP 2C in a Korean population', Clinical Pharmacology and Therapeutics, vol. 61, no. 2, pp. 226.
Ko JW, Macpherson AS, Jang IJ, Shin SG, Flockhart DA. The incidence of genetic polymorphisms of CYP 2C in a Korean population. Clinical Pharmacology and Therapeutics. 1997;61(2):226.
Ko, J. W. ; Macpherson, A. S. ; Jang, I. J. ; Shin, S. G. ; Flockhart, D. A. / The incidence of genetic polymorphisms of CYP 2C in a Korean population. In: Clinical Pharmacology and Therapeutics. 1997 ; Vol. 61, No. 2. pp. 226.
@article{26acf7add6b14b7d882f835b310fa672,
title = "The incidence of genetic polymorphisms of CYP 2C in a Korean population",
abstract = "The distribution of the genetic polymorphism for CYP2C19 in Asians seems different from that in Caucasians. No distribution of the mutations in CYP2C19 or CYP2C9 has been published in a Korean population. We determined the genotypes of 143 healthy, Korean volunteers for CYP2C19 (m1 and m2 mutations) and CYP2C9 (v1 mutation), and compared that to the distribution in a Caucasian population. The m1 and m2 mutations of CYP2C19 appear in significantly greater incidence in this Korean population than Caucasians (p<0.005), but the incidence of the v1 mutation of 2C9 is less in Koreans: P450 Genotypes Korean USA CYP2C19 m1/m1 0.13 0.09 m1/wt 0.39 0.28 m2/m2 0.01 0.00 m2/wt 0.28 0.12 m1/wt and m2/wt 0.09 0.00 CYP2C9 wt/wt 1.00 0.81 v1/v1 0.00 0.01 v1/wt 0.00 0.18 These data suggest that the incidence of Korean genetic poor metabolizers of CYP2C19 (0.22) is relatively large and that the v1 mutation of CYP2C9 is not prominent in Koreans.",
author = "Ko, {J. W.} and Macpherson, {A. S.} and Jang, {I. J.} and Shin, {S. G.} and Flockhart, {D. A.}",
year = "1997",
language = "English",
volume = "61",
pages = "226",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - The incidence of genetic polymorphisms of CYP 2C in a Korean population

AU - Ko, J. W.

AU - Macpherson, A. S.

AU - Jang, I. J.

AU - Shin, S. G.

AU - Flockhart, D. A.

PY - 1997

Y1 - 1997

N2 - The distribution of the genetic polymorphism for CYP2C19 in Asians seems different from that in Caucasians. No distribution of the mutations in CYP2C19 or CYP2C9 has been published in a Korean population. We determined the genotypes of 143 healthy, Korean volunteers for CYP2C19 (m1 and m2 mutations) and CYP2C9 (v1 mutation), and compared that to the distribution in a Caucasian population. The m1 and m2 mutations of CYP2C19 appear in significantly greater incidence in this Korean population than Caucasians (p<0.005), but the incidence of the v1 mutation of 2C9 is less in Koreans: P450 Genotypes Korean USA CYP2C19 m1/m1 0.13 0.09 m1/wt 0.39 0.28 m2/m2 0.01 0.00 m2/wt 0.28 0.12 m1/wt and m2/wt 0.09 0.00 CYP2C9 wt/wt 1.00 0.81 v1/v1 0.00 0.01 v1/wt 0.00 0.18 These data suggest that the incidence of Korean genetic poor metabolizers of CYP2C19 (0.22) is relatively large and that the v1 mutation of CYP2C9 is not prominent in Koreans.

AB - The distribution of the genetic polymorphism for CYP2C19 in Asians seems different from that in Caucasians. No distribution of the mutations in CYP2C19 or CYP2C9 has been published in a Korean population. We determined the genotypes of 143 healthy, Korean volunteers for CYP2C19 (m1 and m2 mutations) and CYP2C9 (v1 mutation), and compared that to the distribution in a Caucasian population. The m1 and m2 mutations of CYP2C19 appear in significantly greater incidence in this Korean population than Caucasians (p<0.005), but the incidence of the v1 mutation of 2C9 is less in Koreans: P450 Genotypes Korean USA CYP2C19 m1/m1 0.13 0.09 m1/wt 0.39 0.28 m2/m2 0.01 0.00 m2/wt 0.28 0.12 m1/wt and m2/wt 0.09 0.00 CYP2C9 wt/wt 1.00 0.81 v1/v1 0.00 0.01 v1/wt 0.00 0.18 These data suggest that the incidence of Korean genetic poor metabolizers of CYP2C19 (0.22) is relatively large and that the v1 mutation of CYP2C9 is not prominent in Koreans.

UR - http://www.scopus.com/inward/record.url?scp=33748957565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748957565&partnerID=8YFLogxK

M3 - Article

VL - 61

SP - 226

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 2

ER -